Central Retinal Vein Occlusion: Etiology, Clinical Presentation and Treatment
DOI:
https://doi.org/10.12775/JEHS.2025.79.58740Keywords
retinal vein occlusion, retina, visual impairmentAbstract
Introduction and Purpose: Retinal vein occlusion (RVO) occurs when the lumen of the retinal vein closes. Central retinal vein occlusion is the second most common retinal vascular disease. There are distinguished forms: central retinal vein occlusion (CRVO), hemiretinal vein occlusion (HRVO) and branch retinal vein occlusion (BRVO). Central retinal vein occlusion is a prevalent cause of visual impairment among the elderly. Currently, there are no proven methods for the prevention of this condition. Current therapy is based on treatment of possible complications (laser therapy, anti-VEGF injections, glucocorticosteroid injections). Central retinal vein occlusion (CRVO) is a disease that involves the sudden appearance of lesions on the fundus due to the closure of a venous vessel. As a result, the patient often experiences a significant deterioration in visual acuity, potentially leading to complete vision loss. Determining the epidemiology is difficult, and diagnosis is based mainly on a physical examination combined with a thorough ophthalmologic evaluation, supplemented by a number of additional tests.
Materials and Methods: A comprehensive survey of articles published in scientific journals was conducted via the online research platforms PubMed and Google Scholar. Articles were searched by entering keywords in the appropriate configuration: “retinal vein occlusion”, “retina”, “visual impairment”.
Description of current knowledge: Studies have indicated that the approach to diagnosing and managing central retinal vein occlusion is largely contingent on the underlying cause and the intensity of the patient's symptoms.
Keywords: “retinal vein occlusion”, “retina”, “visual impairment”
References
[1] “Hayreh S., Prevalent misconceptions about acute retinal vascular occlusive disorders, „Prog Retin Eye Res”2005; 24: 493–519.,”
[2] N. Bhagat, M. F. Goldberg, P. Gascon, W. R. Bell, J. Haberman, and M. A. Zarbin, “Central Retinal Vein Occlusion: Review of Management,” European Journal of Ophthalmology, vol. 9, no. 3. SAGE Publishing, p. 165, Jul. 01, 1999. doi: 10.1177/112067219900900304.
[3] “Hayreh SS, Zimmermann B, McCarthy MJ, Podhajsky P. Systemic diseases associated with various types of retinal vein occlusion. Am J Ophthalmol 2001; 131: 61–77.,”
[4] “Elman MJ, Bhatt AK, Quinlan PM, Enger C. The risk for systemic vascular diseases and mortality in patients with central retinal vein occlusion. Ophthalmology 1990; 97: 1543–1548.,”
[5] “The Central Retinal Vein Occlusion Study Group. Risk factors for central retinal vein occlusion. Arch Ophthalmology 1996; 114: 545–554.,”
[6] “Sperduto RD, Hiller R, Chew E, et al. Risk factors for hemiretinal vein occlusion: comparision with risk factors for central and branch vein occlusion: the eye disease case-control study. Ophthalmology 1998; 105: 765–771.,”
[7] “Klein R, Klein BE, Moss SE, et al. The epidemiology of retinal vein occlusion: Beaver Dam Eye Study. Trans Am Ophthalmol 2000; 98: 133–141.,”
[8] “David R, Zangwill L, Badarna M, et al. Epidemiology of retinal vein occlusion and its association with glaucoma and increased intraocular pressure. Ophthalmologica 1988; 197: 69.,”
[9] “Brown GC. Central retinal vein obstruction: diagnosis and management. In: Reinicke RD (ed). Ophthalmol Annual 1985; 1: 65–97.,”
[10] “Klein R., Klein B.E., Moss S.E., Meuer S.M., The epidemiology of retinal vein occlusion: the Beaver Dam EyeStudy, „Trans Am Ophthalmol Soc”, 2000; 98: 133–143.,”
[11] A. C. O. Fong and H. Schatz, “Central retinal vein occlusion in young adults,” Survey of Ophthalmology, vol. 37, no. 6. Elsevier BV, p. 393, May 01, 1993. doi: 10.1016/0039-6257(93)90138-w.
[12] “Hamid S., Mirza A., Shokh I., Branch retinal vein occlusion, „Journal of Ayub Medical College Abbottabad”2008;20[2]; 128–32.,”
[13] “Kubicka-Trząska A., Romanowska-Dixon B., Diagnosis and management of retinal venous and arterial occlusive disease, „Przew Lek” 2010; 2: 159–164.,”
[14] “Hayreh SS, Zimmerman MB, Podhajsky P. Incidence of various types of retinal vein occlusion and their recurrence and demographic characteristics. Am J Ophthalmol 1994; 117: 429–441.,”
[15] “Wiek J, Schade M, Wiederholt M, et al. Haemorheological changes in patients with retinal vein occlusion isovolaemic haemodilution. Br J Ophthalmol 1990; 74: 665–669.,”
[16] “Arend O, Remky A, Jung F, et al. Role of rheologic factors in patients with acute central retinal vein occlusion. Ophthalmology 1996; 103: 80–86.,”
[17] “Asherson RA, Merry P, Acheson JF, et al. Antiphospholipid antibodies: a risk factor for occlusive ocular vascular disease in systemic lupus erythematosus and the ‘primary’ antiphospholipid syndrome. Ann Rheum Dis 1989; 48: 358–361.,”
[18] “Glacet-Bernard A, Bayani N, Chretien P, et al. Antiphospholipid antibodies in retinal vascular occlusions. A prospective study of 75 patients. Arch Ophthalmol 1994; 112: 790–795.,”
[19] “Abu el-Asar AM, al-Momen AK, al-Amro S, et al. Prothrombotic states associated with retinal venous occlusion in young adults. Int Ophthalmol 1996–1997; 20: 197–204.,”
[20] “McGarth MA, Wechsler F, Hunyor ABL, Penny R. Systemic factors contributory to retinal vein occlusion. Arch Int Med 1978; 138: 216–222.,”
[21] “Ten Doesschate MJL, Manschot WA. Optic disc drusen and central retinal vein occlusion. Documenta Ophthalmol 1985; 59: 27–31.,”
[22] “Galvin R, Sanders MD. Peripheral retinal haemorrhages with papilloedema. Br J Ophthalmol 1980; 64: 262–266.,”
[23] “Schmidt D, Schumacher M, Waklooh AK. Microcatheter urokinase infusion in central retinal artery occlusion. Am J Ophthalmol 1992; 113: 429–434.,”
[24] “Rehak J., Rehak M., Branch retinal vein occlusion: Pathogenesis, visual prognosis, and treatment modalities,„Current Eye Research” 2008; 33: 111–31.,”
[25] X. Zhang et al., “Optical Coherence Tomography Angiography Reveals Distinct Retinal Structural and Microvascular Abnormalities in Cerebrovascular Disease,” Oct. 02, 2020, Frontiers Media. doi: 10.3389/fnins.2020.588515.
[26] N. Gahlaut, S. Suárez, Md. I. Uddin, A. Y. Gordon, S. M. Evans, and A. Jayagopal, “Nanoengineering of therapeutics for retinal vascular disease,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 95. Elsevier BV, p. 323, May 29, 2015. doi: 10.1016/j.ejpb.2015.05.001.
[27] “McIntosh R.L.M., Interventions for Branch Retinal Vein Occlusion, An Evidence-Based Systematic Review, „Ophthalmology” 2007; 114: 835–846.,”
[28] “Gutman FA, Zegarra H. The natural course of temporal retinal branch vein occlusion. Trans Am Acad Ophthalmol Otolaryngol 1974; 78: 178–192.,”
[29] “Branch Vein Occlusion Study Group. Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol 1985; 99: 218–219.,”
[30] “An Informational Guide to CENTRAL RETINAL VEIN OCCLUSION, The Angiogenesis Foundation, 2013.,”
[31] “N. Feucht, E. M. Schönbach, I. Lanzl, C. P. Lohmann, K. Kotliar, and Maier, ‘Changes in the foveal microstructure after intravitreal bevacizumab application in patients with retinal vascular disease,’ Jan. 01, 2013, Dove Medical Press. doi: 10.2147/opth.s37544.,”
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Grzegorz Szcześniak, Aleksandra Kiełczewska, Anna Kiełczewska
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 567
Number of citations: 0
